Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

243.33
-0.1200-0.05%
Post-market: 243.11-0.2200-0.09%19:59 EST
Volume:12.70M
Turnover:3.09B
Market Cap:586.25B
PE:22.06
High:244.49
Open:244.13
Low:241.87
Close:243.45
52wk High:246.35
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.37
T/O Rate:0.53%
Dividend:5.14
Dividend Rate:2.11%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:7.19
PE(LYR):22.05

Loading ...

BRIEF-Ac Immune Says Informed Enrollment Has Been Temporarily Paused For Phase 2B Retain Trial

Reuters
·
3 hours ago

AC Immune Sa: Informed by Janssen Pharmaceuticals That Enrollment Has Been Temporarily Paused for Phase 2B Retain Trial

THOMSON REUTERS
·
3 hours ago

AC Immune Sa: Temporary Pause in Phase 2B Retain Trial Recruitment Is Voluntary & Not Related to New Safety Findings

THOMSON REUTERS
·
3 hours ago

This auto-parts maker is jumping on the breakup bandwagon. Here's why the stock is tanking.

Dow Jones
·
6 hours ago

Johnson & Johnson Says FDA Approved Monthly Dosing of Rybrevant Faspro for EGFR-Mutated Lung Cancer

MT Newswires Live
·
Yesterday

FDA Approves Monthly Dosing for Johnson & Johnson's RYBREVANT FASPRO

Reuters
·
Yesterday

FDA Approves Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) as the Only Egfr-Targeted Therapy That Can Be Administered Once a Month

THOMSON REUTERS
·
Yesterday

J&J: Monthly Dosing Reduces Treatment Visits While Maintaining Established Safety and Efficacy(1,2)

THOMSON REUTERS
·
Yesterday

Compass' psychedelic-based depression treatment scores second late-stage study win

Reuters
·
Yesterday

Why the 'HALO' trade boosting hard assets is no fluke, according to Morgan Stanley

Dow Jones
·
Yesterday

Medtronic beats quarterly profit estimates on robust demand for heart devices

Reuters
·
Yesterday

Should J&J’s Talc Verdict and Mounting Lawsuits Prompt Reassessment From Johnson & Johnson (JNJ) Investors?

Simply Wall St.
·
Yesterday

Assessing Johnson & Johnson (JNJ) Valuation After Fresh Talc Litigation Verdict And Ongoing Legal Risks

Simply Wall St.
·
Feb 16

Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer

Benzinga_recent_news
·
Feb 15

Law firm in J&J baby powder cases sues its litigation funders

Reuters
·
Feb 14

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Reuters
·
Feb 14

Pennsylvania Jury Finds Johnson & Johnson Liable for Woman's Ovarian Cancer - Attorney for National Talc Plaintiffs

THOMSON REUTERS
·
Feb 14

J & J Snack Foods Keeps Quarterly Dividend of $0.80 per Share, Payable April 7 to Shareholders of Record on March 17

MT Newswires Live
·
Feb 13

J & J SNACK FOODS CORP. ANNOUNCES QUARTERLY CASH DIVIDEND

GlobeNewswire
·
Feb 13

Perrigo Co. PLC Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 12